Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients
Received 10 December 2018
Accepted for publication 8 February 2019
Published 5 April 2019 Volume 2019:15 Pages 831—838
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Roger Pinder
József Attila Szász,1,2 Károly Orbán-Kis,1 Viorelia Adelina Constantin,2,3 Csongor Péter,1 István Bíró,1 István Mihály,1,2 Kinga Szegedi,2 Antal Balla,2 Szabolcs Szatmári1,2
1University of Medicine and Pharmacy, Târgu Mureş, Romania; 22nd Neurology Department, Târgu Mureş County Emergency Hospital, Târgu Mureş, Romania; 3Doctoral School, Victor Babes University of Medicine and Pharmacy, Timişoara, Romania
Introduction: In patients older than 70 years there is no valid alternative to progressively introduced substitution therapy. The antiparkinsonian drugs introduced in the last decade to treat Parkinson’s disease, especially in its early phases, promised a comparable efficacy in reducing symptoms to levodopa. In younger patients and/or patients with mild symptoms we hoped to delay the motor complications by postponing the start of levodopa therapy. While these assumptions may not be true for all patients, probably the most important current challenge is the optimal starting moment of levodopa therapy. The aim of the study was to analyze the therapeutical choices during the early phase of Parkinson’s disease in the Neurological Departments of Târgu Mureş County Hospital.
Materials and methods: We examined data obtained from hospitalized Parkinson’s disease patients during a 15-year period. According to the duration of the disease we split the patients into two groups, patients with Parkinson’s disease for less than or equal to 5 years and patients with disease duration longer than 5 years, and then analyzed only the former group.
Results: During the examined period, 2,379 patients with Parkinson’s disease were hospitalized, and 1,237 patients had a disease duration shorter than 5 years. In this group, 18 patients had monoamine oxidase inhibitor monotherapy. Also, 665 patients received dopamine agonists, in 120 cases as monotherapy and in 83 patients associated with monoamine oxidase inhibitors. In 521 patients we found only levodopa treatment. A further 481 patients received combined therapy (levodopa with dopamine agonists and/or monoamine oxidase inhibitors).
Conclusion: Treatment strategies for the early stages of Parkinson’s disease in our group were comparable to results from other studies. However, the authors feel that neurologists should use levodopa-sparing drugs with greater courage. Furthermore, if the clinical context is appropriate, physicians should combine substitution therapy with other antiparkinsonian drugs in order to reduce levodopa doses.
Keywords: Parkinson’s disease, levodopa, dopamine agonist
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]